- Home
- / iNtRON Biotechnology
iNtRON Biotechnology
Stock Price
₩5.8 K
2024-10-29
Market Capitalization
₩192.7 B
2024-10-29
Revenue
₩6.4 B
FY, 2024
iNtRON Biotechnology Summary
Company Summary
- Overview
- iNtRON Biotechnology is a research and development company developing bio-drugs and conducting clinical studies. Its main brand is LiliF Diagnostics that provides molecular diagnostic assays and rapid diagnostic tests.
- Type
- Public
- Status
- Active
- Founded
- 1999
- HQ
- Seongnam-si, KR | view all locations
- Website
- http://www.intronbio.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kevin Yoon, Vice President, Planning and Management
Sang Hyun Kang, Vice President, Research and Development
Operating MetricsView all
Trademarks (US)
2
Jan, 2021
Trademark Applications (US)
2
Jan, 2021
Patent Applications (US)
24
Jan, 2021
LocationsView all
1 location detected
Seongnam-si, Gyeonggi-do HQ
Korea (Republic of)
137 Sagimakgol-ro, Sangdaewon 1(il)-dong, Jungwon-gu
iNtRON Biotechnology Financials
Summary Financials
- Revenue (Q3, 2025)
- ₩4.0B
- Gross profit (Q3, 2025)
- ₩3.2B
- Net income (Q3, 2025)
- (₩4.8B)
- Cash (Q3, 2025)
- ₩29.6B
- EBIT (Q3, 2025)
- (₩5.9B)
- Enterprise value
- $166.2B
Competitors and Similar Companies
- CyanagenManufacturing & Industrial - Private
- Norgen BiotekManufacturing & Industrial - Private
- Zymo ResearchManufacturing & Industrial - Private
- SYSTAAQ Diagnostic ProductsManufacturing & Industrial - Private
- MP BiomedicalsManufacturing & Industrial - Subsidiary
- LucigenManufacturing & Industrial - Subsidiary
- Astra BiotechManufacturing & Industrial - Private